Abstract
▴ Sumatriptan, a serotonin 5-HT1B/1D agonist, constricts cranial blood vessels and inhibits neuroin-flammatory processes.
▴ A single dose of sumatriptan 10mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. Headache relief occurred in significantly more adolescents administered a single dose of intranasal sumatriptan 20mg (at 1 and 2 hours) and 5mg (at 2 hours) than placebo (pooled data from two studies).
▴ Sustained headache relief (1–24 and 2–24 hours) occurred in significantly more recipients of a single dose of intranasal sumatriptan 20mg and 5mg than placebo (pooled data from two studies).
▴ Intranasal sumatriptan was generally well tolerated in adolescent migraineurs (in single-episode studies or long term in multiple-episode studies). Taste disturbance occurred more often with intranasal sumatriptan than with placebo.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994 Sep 24; 309: 765–9
Hämäläinen M, Jones M, Loftus J, et al. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. Int J Clin Pract 2002 Nov; 56(9): 704–9
Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998 Jun; 55(6): 889–922
Winner P, Rothner AD, Putnam DG, et al. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials’ database. Headache 2003 May; 43(5): 451–7
VanDenBrink AM, van den Broek RWM, de Vries R, et al. Human middle meningeal and coronary artery contraction to eletriptan and sumatriptan [abstract no. III-F1-4]. Cephalalgia 1999 May; 19(4): 398
VanDenBrink AM, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998 Jul 7; 98(1): 25–30
Moore KHP, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997 Jun; 17(4): 541–50
Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992 Jun; 106(2): 409–15
Burstein R. Deconstructing migraine headache into peripheral and central sensitisation. Pain 2001; 89: 107–10
Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of sumatriptan nasal spray in adolescents. J Clin Pharmacol 2003 Jul; 43(7): 721–6
Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998 Apr; 6(2): 99–104
Fuseau E, Petricoul O, Moore KHP, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41(11): 801–11
GlaxoSmithKline (US). Imitrex® (sumatriptan) nasal spray: prescribing information 2004 [online]. Available from URL: http://www.gsk.com [Accessed 2004 Sep 24]
GlaxoSmithKline (UK). Imigran® 10mg and 20mg nasal spray: prescribing information 2003 [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2003 Sep 18]
Evans DC, O’Connor D, Scott-Stevens P, et al. Central sites of action affect the antimigraine efficacy of 5-HT1B/1D receptor agonists [abstract]. Headache Q 2001; 12(1): 45
Moore KHP, McNeal S, Britto MR, et al. The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers. Clin Ther 2002 Nov; 24(11): 1887–901
Moore KHP, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther 2002; 24(4): 583–94
Srinivasu P, Rambhau D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol 2000 Jan; 40(1): 99–104
Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991 Nov; 32(5): 581–4
Van Hecken AM, Depré M, De Schepper PJ, et al. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992 Jul; 34(1): 82–4
Fowler PA, Lacey LF, Keene ON, et al. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia 1991 Jun; 11 Suppl. 11: 228–9
Vachharajani NN, Shyu WC, Nichola PS, et al. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Cephalalgia 2002 May; 22(4): 282–7
Winner P, Rothner D, Webster C, et al. Randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology 2004; 62 Suppl. 5: 182
Ahonen K, Hamalainen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004 Mar 23; 62(6): 883–7
Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000 Nov; 106(5): 989–97
Winner P, Rothner AD, Webster C, et al. Overall efficacy of sumatriptan nasal spray in adolescent migraineurs: pooled results from US placebo-controlled trials [abstract]. Plus poster presented at the 46th Annual Scientific Meeting of the American Headache Society 2004 Oct 10–13; Vancouver. Headache 2004; 44(5): 481–2
Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000 Dec; 22(12): 1533–46
Natarajan S, Jabbour JT, Webster CJ, et al. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine. Headache 2004; 44: 969–77
Woodman R. Glaxo rolls out migraine drug imigran nasal spray for adolescents in Europe 2003 [online]. Available from URL: www.medscape.com [Accessed 2003 Sep 15]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Curran, M.P., Evans, H.C. & Wagstaff, A.J. Intranasal Sumatriptan. CNS Drugs 19, 335–343 (2005). https://doi.org/10.2165/00023210-200519040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200519040-00006